2nd. edition
The new edition has been developed to make widely available to programme managers, health care workers in endemic settings, academic researchers, and other key partners, a concise source of information on strategies for MMDP for LF. It is a product of efforts to elaborate and concepts ...and approaches introduced in the previous edition, with a focus on ensuring that countries have the tools necessary to provide the essential package of care for LF.
more
The Handbook is a guide to the normative framework for humanitarian action and the operational approaches, coordination structures, and available tools and services that facilitate the mobilization of humanitarian assistance.
An overview of COVID-19 Vaccine AstraZeneca and why it is authorised in the EU. Available in 22 languages
18 Febr. 2021
abridged version, March 2021
he study highlights the impacts of COVID-19 on women and men as gleaned from research conducted during 2020, as well as the Computer Assisted Telephonic Interviews (CATI) Rapid Gender Assessments (RGAs) executed by UN Women, UNFPA and partners in seven countries in the ...East and Southern Africa region.
more
Health in All Policies (HiAP) is not a new concept. While the term “HiAP” has received much attention since the 1990s, the concept
of working across sectors of government for improved population health and wellbeing is much older than that. Over the last few decades the term has been applied t...o multiple health topics and challenges – whetherimplicitly or explicitly.
more
In 2018, the Intergovernmental Panel on Climate Change announced that to restrict global temperature rise to 1·5°C, greenhouse gas emissions must decrease 45% by 2030 compared with 2010, and reach net zero by 2050.1
Interim guidance 2 march 2021
Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform...ation and a recommendation on hydroxychloroquine. It follows the publication of six trials synthesized in a living network meta-analysis (NMA).
more
21.12.2020
Available in English, Spanish, Italian and Portuguese
Vaccines 2021, 9(2), 160; https://doi.org/10.3390/vaccines9020160
New displacements by conflict and disasters in 2020
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
J of Pharm Policy and Pract 14, 27 (2021). https://doi.org/10.1186/s40545-021-00309-8
1 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
1 February 2021 to 31 January 2022
Vatican lays out 20 points for a universal and fair destination of vaccines, for a fairer and healthier world